Eidos Therapeutics, Inc. appointed William Lis as Board of Directors, effective December 4, 2018.   Mr. Lis has more than 25 years of experience in the biopharmaceutical industry, including serving as chief executive officer of Portola Pharmaceuticals, Inc. William Lis has more than 25 years of biopharmaceutical experience. He served as Chief Executive Officer and a director of Portola Pharmaceuticals, Inc. from 2010 until 2018 after serving as Chief Operating Officer and Chief Business Officer in 2009 and 2008, respectively. Additionally, the company also announced that Hoyoung Huh, MD, PhD, who has served as a member of the company’s Board of Directors since March 2016, has stepped down from his role as a director of the company, effective as of December 4, 2018. Dr. Huh will continue as a consultant to the company through his leadership at BridgeBio Pharma LLC.